Rottapharm
11
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
27.3%
3 terminated/withdrawn out of 11 trials
70.0%
-16.5% vs industry average
18%
2 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
ElectroPoration In a Clinical Setting
Role: collaborator
Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Role: collaborator
Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome
Role: lead
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Role: lead
Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C
Role: lead
Estromineral Serena Plus and Symptomatic Menopause
Role: lead
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
Role: lead
Armolipid Plus and Metabolic Syndrome
Role: lead
DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Role: lead
Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function
Role: collaborator
Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis
Role: lead
All 11 trials loaded